Alzheimer's disease and acetylcholine receptors
Authors:
Open Access
- 31 March 2004
- journal article
- Published by The Nencki Institute of Experimental Biology, Polish Academy of Sciences in Acta Neurobiologiae Experimentalis
- Vol. 64 (1) , 99-105
Abstract
Cholinergic abnormalities, alongside senile plaques, neurofibrillary tangles, and extensive neuronal loss, are the major characteristics in Alzheimer's disease (AD). Both nicotinic and muscarinic acetylcholine receptors are decreased in AD, and it has been shown that the reduction in the number of acetylcholine receptors precedes other pathologic changes. Anti-cholinergic drugs induce amnesia, which can be reversed by withdrawal of the medication. Inhibition of the down-regulation of acetylcholine is, therefore, a strategy for the treatment of AD because it could augment acetylcholine levels within synaptic clefts. In this context, acetylcholinesterase inhibitors, which improve cognitive functions, are currently approved for the treatment of AD. Stimulation of acetylcholine receptors, nicotinic or muscarinic, is another strategy; some drugs are currently under investigation, and reported to be effective. In addition, nicotinic stimulation exerts a neuroprotective effect, and reduces the amyloid burden. Cholinergic therapy may counter the symptoms and progress of AD.Keywords
This publication has 27 references indexed in Scilit:
- Memory-related task performance by aged rhesus monkeys administered the muscarinic M 1 -preferring agonist, talsaclidinePsychopharmacology, 2002
- Nicotinic receptor abnormalities of Alzheimer’s disease: therapeutic implicationsBiological Psychiatry, 2001
- Risk factors accelerating cerebral degenerative changes, cognitive decline and dementiaInternational Journal of Geriatric Psychiatry, 1999
- Four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer's diseasePsychopharmacology, 1999
- Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's diseasePsychopharmacology, 1999
- Nicotinic receptor stimulation protects neurons against β‐amyloid toxicityAnnals of Neurology, 1997
- Cell death induced by β-amyloid 1–40 in MES 23.5 hybrid clone: the role of nitric oxide and NMDA-gated channel activation leading to apoptosisBrain Research, 1995
- Tobacco consumption and cognitive impairment in elderly people a population-based studyAnnals of Epidemiology, 1994
- Nicotinic acetylcholine binding sites in Alzheimer's diseaseBrain Research, 1986
- Studies on human memory: The interactions of diazepam, scopolamine, and physostigminePsychopharmacology, 1977